MDOTM Ltd Closes $27.

Be.EV

Be.EV is the UK’s 2nd highest rated rapid/ultra-rapid charging network as voted by EV drivers themselves (Zapmap 2025/medium sized). This is a testament to our mission to listen to customers and to give them what they want: publicly accessible, rapid and ultra-rapid charging hubs conveniently located on busy routes, at dwell destinations and in the hearts of communities nationwide. We are proud to be majority owned by Octopus Energy Generation – one of Europe’s largest renewable energy investors. We currently manage a growing network of over 800 charging bays across the UK. Be.EV is majority owned by Octopus Energy Generation with the wider Octopus Energy group supplying the network with deep green energy powered by wind and solar – traceable back to its source. Our mission to is help every driver love every electric journey by giving our customers what they want: publicly accessible, rapid and ultra-rapid charging hubs, conveniently located on busy routes or at popular dwell destinations – and in the hearts of communities nationwide. We realise not everyone has the benefit of a home charger – and we are committed to ensure switching to an EV is an accessible choice for all. We are relentless in our pursuit of the best possible customer experience, and that means clean and welcoming sites, easy to use app and chargers, greater liability and fair pricing. By putting the right charging kit in the right places, and listening to what our active 60k members want, we strive to drive charging delight every time. We hope to play our part in accelerating EV take up in the UK and to shape cleaner and greener neighbourhoods of the future.

4BIO Capital

4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector. 4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space. For more information, please visit www.4biocapital.com

Gaussion

Gaussion creates energy intelligence - the intelligent control layer inside every battery pack. A UK deep tech company spun out from UCL in 2022. Our magnetic chips retrofit into existing battery systems without changing cells, chemistry, or supply chains. The result: longer cycle life, better cold weather performance, and real-time data from inside the pack.

UBDS Digital

UBDS Digital, a brand on a mission to deliver unparalleled client value, unmatched employee experience, and to make a meaningful difference in society. We understand your needs deeply and are laser focused on outcomes, never compromising on quality or security. We are your visionary partner, taking on complex work, creating smarter solutions, with innovative technologies, for the best results and producing lasting progress, for all. In September 2024, UBDS Digital became B Corp Certified. This certification affirms our commitment to purpose-driven practices and using business as a force for positive change. We are proud to align each project with the broader mission of benefiting all stakeholders, not just shareholders, and to be part of a movement of forward-thinking companies that prioritise societal impact.

Oxford Drug Design

Oxford Drug Design, an advanced spinout from Oxford University, is an innovative biotechnology company discovering and developing novel therapeutics supported by pioneering computational methods. We design innovative drugs with differentiated modes of action against cancer and other challenging diseases with high unmet medical need seeking superior patient outcomes. Based on the unique integration of our dual core competences in aminoacyl-tRNA synthetase enzymes and distinctive AI/ML methods, our pipeline expansion is focused on oncology. This distinctive drug discovery platform has been validated by the rapid discovery of novel therapeutic candidates with highly innovative chemical scaffolds and modes of action.